Terminology Service < Semantic Lookup Platform

All terms in EFO

Label	Id	Description
asthma	MONDO_0004979	[A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.]
interstitial lung disease	EFO_0004244	[A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features., A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.]
lung	UBERON_0002048	[Respiration organ that develops as an outpocketing of the esophagus.]
chronic obstructive pulmonary disease	EFO_0000341	[A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema., A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA., A group of disorders affecting the bronchi and the lung parenchyma. It is characterized by chronic and irreversible obstruction of the airflow. It includes chronic bronchitis and pulmonary emphysema.]
lysophosphatidylcholine 16:1 measurement	EFO_0010358	[The quantification of lysophosphatidylcholine 16:1 levels in a sample.]
GM17118	CLO_0014951	[UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100]
diacylglycerol 36:2 measurement	EFO_0010355	[The quantification of diacylglycerol 36:2 levels in a sample.]
diglyceride measurement	EFO_0010223	[A quantification of diglycerides.]
GM17115	CLO_0014952	[HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1]
lysophosphatidylcholine 14:0 measurement	EFO_0010356	[The quantification of lysophosphatidylcholine 14:0 levels in a sample.]
GM17116	CLO_0014953	[HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24]
non-allergic rhinitis	EFO_0009364	[Nonallergic rhinitis has the same symptoms as allergic rhinitis, but in the absence of allergic sensitization, typically evaluated by measurement of specific IgEs or skin-prick test against a range of allergens.]
rhinitis	EFO_0008521	[Rhinitis is an inflammation of the lining of the nose. It is defined clinically as symptoms of runny nose itching, sneezing and nasal blockage (congestion)., An inflammation of the mucous membrane lining the nose, usually associated with nasal discharge.]
diacylglycerol 34:2 measurement	EFO_0010353	[The quantification of diacylglycerol 34:2 levels in a sample.]
diacylglycerol 36:1 measurement	EFO_0010354	[The quantification of diacylglycerol 36:1 levels in a sample.]
vaginal inflammation	EFO_0005757	[local accumulation of fluid, plasma proteins, and leukocytes in the vagina]
quality of life during menstruation measurement	EFO_0009366	[A measure to assess quality of life (QOL) based on how the individual has felt during the menstrual period.]
health-related quality of life measurement	EFO_0011014	[A measure to assess health-related quality of life (HRQOL), which domains include physical health, emotional health, cognitive functioning, fatigue and pain.]
lipid measurement	EFO_0004529	[A measure of circulating lipid]
glucose metabolism measurement	EFO_0009367	[Quantification of a glucose metabolic process.]